Century Therapeutics, Inc.
IPSC
$0.52
-$0.0018-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,457.09% | 434.46% | 678.79% | -50.29% | -48.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,457.09% | 434.46% | 678.79% | -50.29% | -48.56% |
| Cost of Revenue | 31.75% | 19.48% | 19.77% | -5.94% | -12.86% |
| Gross Profit | -14.41% | -16.77% | -16.89% | 2.64% | 12.11% |
| SG&A Expenses | 6.08% | -7.06% | 0.94% | -1.79% | 4.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.61% | 11.98% | 14.76% | -4.84% | -8.70% |
| Operating Income | -12.07% | -10.00% | -12.63% | 2.41% | 8.07% |
| Income Before Tax | 14.83% | 2.78% | 3.57% | 6.64% | -27.23% |
| Income Tax Expenses | 304.37% | -101.35% | -97.68% | -99.92% | -2,815.63% |
| Earnings from Continuing Operations | 8.44% | 4.57% | 6.26% | 10.24% | -24.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.44% | 4.57% | 6.26% | 10.24% | -24.35% |
| EBIT | -12.07% | -10.00% | -12.63% | 2.41% | 8.07% |
| EBITDA | -14.52% | -11.37% | -13.29% | 3.74% | 11.17% |
| EPS Basic | 35.69% | 33.03% | 32.35% | 15.54% | -20.85% |
| Normalized Basic EPS | 18.87% | 22.05% | 19.96% | 12.17% | 16.74% |
| EPS Diluted | 35.69% | 33.03% | 32.35% | 15.54% | -20.85% |
| Normalized Diluted EPS | 18.87% | 22.05% | 19.96% | 12.17% | 16.74% |
| Average Basic Shares Outstanding | 42.37% | 42.48% | 38.55% | 6.29% | 2.90% |
| Average Diluted Shares Outstanding | 42.37% | 42.48% | 38.55% | 6.29% | 2.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |